Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier, William Rastetter, Richard Lingard, John DelliSanti

BIOCOM, a Southern California life sciences trade association, said this week that it has named eight new members to its board of directors. Invitrogen Chairman and CEO Greg Lucier is chairman of the board for 2007-2008.
Among the other board members is William Rastetter, who is a venture partner for Venrock Associates, a former chairman of BIOCOM, and currently serves as chairman of the board of Illumina.

DeltaDot this week said it has named Richard Lingard vice president of sales. Lingard previously was a director of strategic alliances at Invitrogen, vice president of business development at Argenta Discovery, director of business development at Inpharmatics, and was a sales director at Genomica. Lingard also served in business positions at Accelrys and at Merck.

Caliper Life Sciences has named John DelliSanti to the position of executive vice president and chief commercial officer. In this post he will lead Caliper’s worldwide sales, marketing, and services efforts.
DelliSanti joins Caliper from Invitrogen, where he led the Americas commercial operations. He has also held positions at Accelrys, Wyeth Pharmaceuticals, and Hitachi Instruments.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.